Trial · NCT07359248
Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache
NCT07359248, Not applicable, Active not recruiting, Tongji Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache. Trials, record NCT07359248. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07359248
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache
- NCT number
- NCT07359248
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 432 participants, estimated
- Lead sponsor
- Tongji Hospital
- Conditions
- Tension Type Headache
- Interventions
- Desvenlafaxine, Placebo
- First posted
- 2026-01-22
- Last updated
- 2026-01-22
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Days with tension-type headache (TTH) during the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) | During the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) | Days with tension-type headache (TTH) during the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) |
| Secondary | Total headache index AUC (area under the curve) during the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) | during the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) | Total headache index AUC (area under the curve) during the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) |
| Secondary | Headache severity (VAS 0-10) and duration (hours per day) during the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) | during the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) | Headache severity (VAS 0-10) and duration (hours per day) during the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) |
| Secondary | Acute analgesic consumption: number of days and dosage | during the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) | Acute analgesic consumption: number of days and dosage |
| Secondary | Treatment effectiveness criterion: reduction in headache days by ≥50% during the third 4-week intervention period compared to the screening period | during the third 4-week intervention period | Treatment effectiveness criterion: reduction in headache days by ≥50% during the third 4-week intervention period compared to the screening period |
| Secondary | Safety assessment and tolerability evaluation | During the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) | Safety and tolerability will be evaluated by: Continuous recording of treatment-emergent adverse events (TEAEs, graded by CTCAE v5.0) throughout the study. |
| Secondary | Change in headache impact on daily life as assessed by the 6-item Headache Impact Test (HIT-6) total score | During the 12-week intervention period (reported in 4-week intervals: Weeks 0-4, 5-8, and 9-12) | The HIT-6 questionnaire measures the adverse impact of headache on daily functioning in six domains (pain, social functioning, role functioning, vitality, cognitive functioning, psychological distress). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07359248
GET https://conductscience.org/api/trials/v1/NCT07359248/registered